Infectives vaccine partnering terms and agreements

123 views
85 views

Published on

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
123
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Infectives vaccine partnering terms and agreements

  1. 1. Infectives Vaccine Partnering Terms and Agreements The Infectives vaccine partnering terms and agreements report provides a detailed understanding and analysisof how and why companies enter infectives vaccine partnering deals. The majority of deals are developmentstage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. Thesedeals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Thereport also includes adjuvant deals and alliances. This report provides details of the latest infectives vaccine agreements announced in the healthcare sectors. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insightinto the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilstmany smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms ofhow payments are triggered – contract documents provide this insight where press releases anddatabases do not. This report contains a comprehensive listing of all infectives vaccine partnering deals announced sinceJanuary 2007, including financial terms where available, including over 300 links to online deal records ofactual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records includecontract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’sflexibility on a wide range of important issues, many of which will have a significant impact on eachparty’s ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What arethe precise rights granted or optioned? What is the payment structure for the deal? How aresalesand paymentsaudited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled andowned? Who is responsible for commercialization? Who is responsible for development, supply, andmanufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under whatconditions can the deal be terminated? What happens when there is a change of ownership? What sublicensingand subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Whichjurisdiction does the company insist upon for agreement law? The initial chapters of this report provide anorientation of infectives vaccine dealmaking and business activities. Chapter 1 provides an introduction to thereport, whilst chapter 2 provides an overview of the trends in infectives vaccine dealmaking since 2007,including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading infectives vaccine deals since 2007. Deals are listed by headlinevalue, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where thedeal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive and detailed review of infectives vaccine partnering deals signed andannounced since January 2007, where a contract document is available in the public domain. The chapter isorganized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion,licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the dealInfectives Vaccine Partnering Terms and Agreements
  2. 2. record and where available, the contract document, providing easy access to each contract document ondemand. The report also includes numerous tables and figures that illustrate the trends and activities in infectivesvaccine partnering and dealmaking since 2007. In conclusion, this report provides everything a prospectivedealmaker needs to know about partnering in the research, development and commercialization of infectivesvaccine technologies and products. Report scope Infectives Vaccine Partnering Agreements is intended to provide the reader with an in-depth understandingand access to infectives vaccine trends and structure of deals entered into by leading companies worldwide. Infectives Vaccine Partnering Agreements includes: Trends in infectives vaccine dealmaking in the biopharma industry since 2007 Analysis of infectives vaccinedeal structure Access to headline, upfront, milestone and royalty data Access to over 600 cancer vaccine dealrecords The leading infectives vaccine deals by value since 2007 Includes adjuvant and drug delivery dealsand alliances since 2007 In Infectives Vaccine Partnering Agreements, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific oncologytherapy target Each deal title links via Weblink to an online version of the deal record and where available, the contractdocument, providing easy access to each contract document on demand. The Infectives Vaccine Partnering Agreements report provides comprehensive access to available deals andcontract documents for over 600 infectives vaccine deals. Analyzing actual contract agreements allowsassessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partnercompany? What exclusivity is granted? What is the payment structure for the deal? How aresalesand paymentsaudited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled andowned? Who is responsible for commercialization? Who is responsible for development, supply, andmanufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under whatconditions can the deal be terminated? What happens when there is a change of ownership? What sublicensingand subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdictiondoes the company insist upon for agreement law? Benefits In-depth understanding of dental deal trends since 2007 Access dental deal headline, upfront, milestone androyalty data Research hundreds of actual contracts between dermatology partner companies Comprehensiveaccess to over 1500 links to actual dermatology deals entered into by the world’s biopharma companiesIndepth review of dental deals entered into by the leading fifty bigpharma companies Benchmark the key dealterms companies have agreed in previous deals Identify key terms under which companies partnerdermatology opportunities Uncover companies actively partnering dermatology opportunities Report scope Dermatology Partnering Terms and Agreements is intended to provide the reader with an in-depthunderstanding and access to dermatology trends and structure of deals entered into by leading companiesworldwide. Dermatology Partnering Terms and Agreements includes: Trends in dermatology dealmaking in the biopharma industry since 2007 Analysis of dermatology dealstructure Access to headline, upfront, milestone and royalty data Access to hundreds of dermatology dealInfectives Vaccine Partnering Terms and Agreements
  3. 3. contract documents Comprehensive access to over 1500 dermatology deal records The leading dermatologydeals by value since 2007 Most active dermatology dealmakers since 2007 In Dermatology Partnering Termsand Agreements, available deals and contracts are listed by: Headline value o Upfront payment value Royaltyrate value o Stage of development at signing Deal component type Technology type Specific therapyindication Each deal title links via Weblink to an online version of the deal record and where available, thecontract document, providing easy access to each contract document on demand.table Of Contentsexecutive Summarychapter 1 – Introductionchapter 2 – Trends In Infectives Vaccine Dealmaking2.1. Introduction2.2. Infectives Vaccine Partnering Over The Years2.3. Bigpharma Infectives Vaccine Dealmaking Activity2.4. Bigpharma Not Active In Infectives Vaccine Partnering2.5. Infectives Vaccine Partnering By Deal Type2.6. Infectives Vaccine Partnering By Stage Of Development2.7. Infectives Vaccine Partnering By Infectives Indication2.8. Disclosed Deal Terms For Infectives Vaccine Partnering2.8.1 Infectives Vaccine Partnering Headline Values2.7.2 Infectives Vaccine Deal Upfront Payments2.7.3 Infectives Vaccine Deal Milestone Payments2.7.4 Infectives Vaccine Royalty Rateschapter 3 – Leading Infectives Vaccine Deals3.1. Introduction3.2. Top Infectives Vaccine Deals By Valuechapter 4 – Infectives Vaccine Dealmaking Directory4.1. Introduction4.2. Company A-z4.3. By Stage Of Developmentdiscoverymarketedphase IInfectives Vaccine Partnering Terms and Agreements
  4. 4. phase Iiphase Iiipre-clinical4.4. By Deal Typeasset Purchaseassignmentbigpharma Outlicensingco-developmentcollaborative R&dco-marketcontract Serviceco-promotioncradacross-licensingdevelopmentdistributionequity Purchaseevaluationgrantjoint Venturelicensingmanufacturingmarketingmaterial Transferoptionpromotionresearchroyalty Financingsettlementspin Outsub-licensesupplytechnology Transferterminationwarranty4.5. By Infectives Therapy Areainfectives4.6. By Related Technologyvaccineschapter 5 –partnering Resource Center5.1. Online PartneringInfectives Vaccine Partnering Terms and Agreements
  5. 5. 5.2. Partnering Events5.3. Further Reading On Dealmakingappendicesappendix 1 – Deal Type Definitionsappendix 2 – Example Infectives Vaccine Partnering Agreementabout Wildwood Venturescurrent Partneringcurrent Agreementscurrent Reportsrecent Report Titles From Currentpartneringorder Form – Therapy ReportsAbout Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Infectives Vaccine Partnering Terms and Agreements

×